November 19th, 2014
Today, November 19th, Janssen proudly supports World Chronic Obstructive Pulmonary Disorder (COPD) Day, an annual event organized by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to raise awareness and improve care for obstructive lung diseases.
COPD is a progressive lung disease that interferes with airflow, making it difficult to breathe. Emphysema and chronic bronchitis are terms often used to describe types of COPD. More than 64 million people worldwide are living with COPD, and while core symptoms include cough, phlegm, and shortness of breath it can be life threatening. In fact, the World Health Organization estimates that COPD will become the third-leading cause of death globally by 2030. This staggering statistic speaks volumes, especially considering that COPD is treatable, although not curable.
At Janssen, we have made great strides to deepen our understanding of patient needs and build a strong network of skilled scientists and experts with deep disease understanding, while seeking collaborative efforts to develop future treatments that are safe, effective and accessible for patients. With a portfolio of promising therapies, Janssen strives to go beyond the current standard of care to not only treat the core symptoms of disease, but one day stop disease progression or even prevent COPD.